Since women with certain BRCA1 and BRCA2 germline mutations are at higher risk of developing breast cancer and ovarian cancer, identification of these harmful mutations can alert health care providers of the need for enhanced cancer surveillance in this subset of patients for early detection and the possibility of preventive interventions. This evidence concerns the gene BRCA2 and breast carcinoma.